1. The Ademi Firm is investigating VYNE for fiduciary duty breaches. 2. VYNE shareholders will only own 3% post-merger with Yarrow. 3. Transaction limits competing offers and imposes penalties on VYNE.
FAQ
Why Bearish?
The investigation raises concerns regarding VYNE's management decisions, similar to past shareholder litigation outcomes. Companies facing such litigation often see stock price declines as trust erodes.
How important is it?
The investigation's implications for fiduciary responsibilities could severely impact VYNE's market image and shareholder confidence.
Why Short Term?
Investor sentiment may be affected quickly due to legal uncertainties and potential shareholder actions, affecting VYNE in the immediate future.
MILWAUKEE, Dec. 18, 2025 /PRNewswire/ -- The Ademi Firm is investigating VYNE (NASDAQ:VYNE) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Yarrow Bioscience.
Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you.
In the transaction, VYNE shareholders will receive the pre-Merger VYNE stockholders are expected to own approximately 3% of the combined company, and the pre-Merger Yarrow stockholders are expected to own approximately 97% of the combined company. VYNE insiders will receive substantial benefits as part of change of control arrangements.
The transaction agreement unreasonably limits competing transactions for VYNE by imposing a significant penalty if VYNE accepts a competing bid. We are investigating the conduct of the VYNE board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.
We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.
Contacts
Ademi & Fruchter LLP
Guri Ademi
Toll Free: (866) 264-3995
Fax: (414) 482-8001
View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholder-alert-the-ademi-firm-investigates-whether-vyne-therapeutics-inc-is-obtaining-a-fair-price-for-its-public-shareholders-302646437.html
SOURCE Ademi LLP